Cannabinoids for Severe Itching: Medical Case Studies

Medical cannabis case studies · Literature checked 2 October 2026

Severe itching can dominate a person’s life even when the skin shows little primary inflammation. Among the more unusual therapeutic observations in cannabinoid medicine are reports of prescribed dronabinol bringing relief after numerous other treatments had failed. These are interesting clinical signals, but they do not establish a general treatment for itching.

Evidence at a glance: small, uncontrolled case series; oral prescription THC; encouraging symptom reports; no reliable estimate of how often another patient would benefit.

Simple drawing of a nerve cell with branching dendrites, a cell body, a long axon and terminal branches. — A nerve-cell illustration provides context for neuropathic symptoms; it does not depict a proven mechanism of cannabinoid itch relief. Dana Scarinci Zabaleta, 2019, via Wikimedia Commons. CC0 public-domain dedication.

Two striking examples of neuropathic itch

A 2021 specialist-clinic series described three patients receiving dronabinol. Two examples illustrate the range. A 64-year-old woman with cervical disc disease and brachioradial pruritus had four years of severe upper-body itching. Her reported severity fell from as high as 10/10 to 0–1/10, with follow-up exceeding four years. A 54-year-old woman with longstanding vulvar burning and itching had extensive negative investigations and unsuccessful treatments. After prescribed dronabinol, symptoms also fell to 0–1/10 and remained controlled during 2.5 years of follow-up. The treatment was a measured oral THC medicine. These observations concern a suspected nerve-related problem, not evidence that cannabis treats every skin disorder. [1]

An earlier report in cholestatic liver disease

Neff and colleagues reported a different setting in 2002: three patients with severe itching associated with impaired bile flow. Extensive previous treatment had failed, and the symptom disrupted sleep and work. Following prescribed dronabinol, all reported less itching, improved sleep and eventual return to work. One developed impaired coordination, which resolved after the dose was reduced. This was an uncontrolled observation involving only three patients. It offers a separate signal of possible symptom relief, not evidence that the underlying liver disease improved. [2]

Why the distinction between symptom and disease matters

The interesting question is whether a cannabinoid can reduce a particular distressing sensation. That is narrower than asking whether it repairs damaged nerves, reverses a liver disorder or removes the original cause. A patient’s ability to sleep or work again is meaningful, but those improvements cannot by themselves identify what the medicine changed biologically.

These two settings also should not be merged into a single diagnosis. A shared symptom does not imply a shared cause. A future trial would need to specify which patients it enrolled and what other treatments they were receiving before making a credible claim about effectiveness.

What strengthens the reports, and what remains uncertain?

For interpreting unusual treatment responses, useful features include a clear pretreatment history, a recorded symptom score, a documented product and follow-up beyond the first few days. Even when those features are present, an uncontrolled report lacks a comparison group. It cannot separate the treatment effect from expectation, fluctuating symptoms, concurrent care or selective publication.

The key missing number is the denominator: how many similar patients tried the treatment without benefit, stopped because of adverse effects, or were never written up? A series of successful cases is not a success rate. Nor does a large improvement on a self-reported scale prove that an underlying abnormality has resolved. The appropriate next step for research is a controlled study with predefined outcomes and systematic recording of harms.

Why dronabinol is not interchangeable with CBD oil

Dronabinol is a pharmaceutical form of delta-9-THC. Its US prescribing information lists specific appetite and chemotherapy-related indications, not itching. It also warns about altered thinking, psychiatric effects, changes in blood pressure or heart rate and impaired ability to perform hazardous activities. These risks remain relevant when a medicine is being considered for an unusual, off-label purpose. [3]

A report involving prescribed oral THC cannot establish the effectiveness of an over-the-counter CBD preparation, a topical cream or a different cannabis product. Product identity is part of the evidence, not a minor detail. Likewise, a dose used in a published case should not be treated as a personal dosing instruction.

Questions worth taking to a clinical appointment

A useful discussion starts with the diagnosis: what is thought to be causing the itch, what investigations support that explanation, and which established options remain? If an off-label treatment is considered, the patient and clinician can agree what improvement would count, how alertness and daily functioning will be assessed, and when treatment will be reviewed. A symptom diary can make that conversation more specific than a general impression that something helped.

This article explains published clinical evidence. Individual cases cannot predict personal treatment response. Decisions about prescription medicines belong with the treating clinician.